Alkem Laboratories Limited (ALKEM)

Name: Alkem Laboratories Limited (ALKEM) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-09-20

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally.

Dati chiave

Capitalizzazione di mercato: ₹654 billion
Ricavi (esercizio chiuso a 2026-03-31): ₹145.3B
Utile netto: ₹23.0B
Margine lordo: 64.2%
Margine netto: 15.8%

Vedi grafici interattivi e bilanci completi →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Entrate totali	₹145.3B	₹128.0B	₹124.4B	₹114.4B	—
Utile lordo	₹93.3B	₹79.5B	₹74.1B	₹64.6B	—
Risultato Operativo (EBIT)	₹26.5B	₹21.8B	₹19.8B	₹13.3B	—
Reddito netto	₹23.0B	₹21.7B	₹18.0B	₹9.8B	—

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di ALKEM. /companies/us/ALKEM

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.